SlideShare uma empresa Scribd logo
1 de 39
TUMOR CELL
TUMOR ANTIGENS SWATHI PRABHAKAR
[810014214042]
III Year, B.Tech Biotech
Anna university [BIT Campus]
Trichy 620 024
swathipriyabiotechautbit@gmail.com
 Tumor antigen is an antigenic
substance produced in tumor cells.
i.e., it triggers an immune response
in the host.
 These antigens are not membrane
proteins but are derivatives of cytosolic
proteins.
i.e.,peptides of cytosolic proteins
Two types of tumor antigens have been
identified on tumor cells:
1. Tumor-Specific Transplantation Antigens
(TSTAs)
E.g. : Abnormal products of ras and p53 genes
2. Tumor-Associated Transplantation Antigens
(TATAs)
E.g. : Epidermal growth factor (EGF) like p97
Two genes-
red and blueTwo
proteins-
red and blue
Mutated
Pink gene
New altered protein
Irregular gene
expression
- Black colour
Unwanted
protein
production
Over expressed
Normal gene
Abnormal protein
concentration
1. Unique to tumor cells
2. Do not occur on normal cells in the body.
3. TSTA produced due to physical, chemical or
viral mutagens
4. Mutation results in altered cellular proteins.
This cellular proteins on cytosolic processing
results in novel peptides i.e. tumor antigen
4. This tumor antigen induces cell-mediated
immune response by tumor-specific
cytosolic T-cell (CTLs)
5. The immune system detects and eliminates
these tumor cells by the antigens on the cell
surface.
• Tumor-associated antigens are not unique to
tumor cells.
• These are proteins that are expressed on
normal cells during fetal development when the
immune system is immature and unable to
respond but that normally are not expressed in
the adult.
• Reactivation of the embryonic genes that
encode oncofetal proteins in tumor cells
results in their expression on the fully
differentiated tumor cells.
• Tumor-associated antigens may also be
proteins that are normally expressed at
extremely low levels on normal cells but are
expressed at much higher levels on tumor
cells.
• For example, Transferrin growth factor,
designated p97, which aids in the transport of
iron into cells. Whereas normal cells express
less than 8,000 molecules of p97 per cell,
melanoma cells express 50,000–500,000
molecules of p97 per cell
1. Antigens encoded by genes exclusively
expressed by tumors.
2. Antigens encoded by variant forms of normal
genes that have been altered by mutation.
3. Antigens normally expressed only at certain
stages of differentiation or only by certain
differentiation lineages.
4. Antigens that are over expressed in particular
tumors
Following are causes of TSTA Production:
1. Chemical agents E.g. : Methylcholanthrene
2. Physical agents E.g. : Ultraviolet light
3. VIRUS E.g. : Polyoma virus (PV)
1. Chemical agents/ Physical agents
-Antigens’ nature varies with respect to
1.1. The type of tissue administered
1.2. The dosage
2. VIRUS
- Antigens are specific only to strain
irrespective of tissue and concentration.
1 2
1
2
• In one method, peptides bound to class I MHC molecules on
the membranes of the tumor cells are eluted with acid and
purified by high-pressure liquid chromatography (HPLC). In
some cases, sufficient peptide is eluted to allow its sequence
to be deduced by Edman degradation.
In a second approach, cDNA libraries are prepared from tumor cells. These
cDNA libraries are transfected transiently into COS cells, which are monkey
kidney cells transfected with the gene that codes for the SV40 large-T
antigen. When these cells are later transfected with plasmids containing
both the tumor-cell cDNA and an SV40 origin of replication, the large-T
antigen stimulates plasmid replication, so that up to 104–105 plasmid
copies are produced per cell. This results in high-level expression of the
tumor-cell DNA.
1. ONCOFETAL TUMOR ANTIGENS
E.g. :1. Alpha-fetoprotein (AFP) -Liver cancer
2.Carcinoembryonic antigen (CEA)- advanced
Colorectal cancer
2. ONCOGENE PROTEINS AS TUMOR ANTIGENS
E.g. : Human breast-cancer cells -Neu protein
Tumor antigens
Cell-mediated immune
responses
Humoral immune
responses
IMMUNE
SYSTEM
IMMUNE
SYSTEM
(Major)
(Minor)
TSTAs CTLs produced
against tumor antigens
But MHC count on tumor
cells reduces thus limiting
CTLs
Tumor antigens are
displayed by class I MHC
The recognition of tumor cells by NK
cells is MHC
restricted
Fc receptors on NK cells can bind
to antibody-coated tumor cells, leading
to ADCC.
The recognition of tumor cells by macrophages
are not MHC restricted
Macrophages
cluster around
Tumor cells
Mediates ADCC
utilising lytic
enzymes,
ROS,RNS.
Macrophages produces cytokine –
“TNF alpha” induceing hemorrhage
and necrosis of the tumor.
Immune surveillance theory conceptualized by Paul
Ehrlich-states “cancer cells frequently arise in the body but are
recognized as foreign and eliminated by the immune system”
Later Lewis Thomas suggested that the cell-mediated branch of
the immune system had evolved to patrol the body and eliminate
cancer cells.
Impairment in the immune response results in cancer.
1.Nude mice (Lacking thymus and functional T cells) shows no
susceptible to cancer.
2. Individuals on immunosuppressive drugs do show an increased
incidence of cancers of the immune system, other common
cancers (e.g., lung, breast, and colon cancer) are not increased in
these individuals, contrary to what the theory predicts
3. Effect of tumor-cell dosage on the ability of the immune
system to respond also are incompatible with the immune
surveillance theory. For example, animals injected with very low
or very high doses of tumor cells develop tumors, whereas those
injected with intermediate doses do not. The mechanism by
which a low dose of tumor cells “sneaks through” is difficult to
reconcile with the immune surveillance theory
1.Finally, this theory assumes malignant tumors arise only if the
immune system is somehow impaired or if the tumor cells lose
their immunogenicity, enabling them to escape immune
surveillance
2. Cancer cells and normal cells exhibit qualitative antigen
differences
3. An immune response can be generated to tumor cells, and
therapeutic approaches aimed at increasing that response may
serve as a defense against malignant cells tumor evasion of the
Immune
-ROBERT GREEN INGERSOLL

Mais conteúdo relacionado

Mais procurados

Antibody diversity presentation
Antibody diversity presentationAntibody diversity presentation
Antibody diversity presentationFaris K
 
2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptens2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptenstaha244ali
 
Antigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsAntigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsSaranraj P
 
Monoclonal and Polyclonal Antibodies
Monoclonal and Polyclonal AntibodiesMonoclonal and Polyclonal Antibodies
Monoclonal and Polyclonal AntibodiesRafat F Chowdhury
 
T CELL ACTIVATION AND IT'S TERMINATION
T CELL ACTIVATION AND IT'S TERMINATIONT CELL ACTIVATION AND IT'S TERMINATION
T CELL ACTIVATION AND IT'S TERMINATIONpremvarma064
 
Cells of the immune system ppt
Cells of the immune system pptCells of the immune system ppt
Cells of the immune system pptGloria Okenze
 
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANS
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANSORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANS
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANSSruthy Chandran
 
Cells of the immune system
Cells of the immune systemCells of the immune system
Cells of the immune systemPraveen Garg
 
The complement system
The complement systemThe complement system
The complement systemsushma93
 
T and B cell activation
T  and B cell activationT  and B cell activation
T and B cell activationyashi jain
 
Major Histocompatibility complex
Major Histocompatibility complexMajor Histocompatibility complex
Major Histocompatibility complexPrasann Saha
 

Mais procurados (20)

Antibody diversity presentation
Antibody diversity presentationAntibody diversity presentation
Antibody diversity presentation
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
T-cell
T-cellT-cell
T-cell
 
Cytokines
CytokinesCytokines
Cytokines
 
2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptens2 antigens, immunogens, epitopes, and haptens
2 antigens, immunogens, epitopes, and haptens
 
Antigens, Haptens and Adjuvants
Antigens, Haptens and AdjuvantsAntigens, Haptens and Adjuvants
Antigens, Haptens and Adjuvants
 
B cell(Immunology)
B cell(Immunology)B cell(Immunology)
B cell(Immunology)
 
IMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORSIMMUNE RESPONSE TO TUMORS
IMMUNE RESPONSE TO TUMORS
 
Monoclonal and Polyclonal Antibodies
Monoclonal and Polyclonal AntibodiesMonoclonal and Polyclonal Antibodies
Monoclonal and Polyclonal Antibodies
 
Cytokines
Cytokines Cytokines
Cytokines
 
T CELL ACTIVATION AND IT'S TERMINATION
T CELL ACTIVATION AND IT'S TERMINATIONT CELL ACTIVATION AND IT'S TERMINATION
T CELL ACTIVATION AND IT'S TERMINATION
 
Cytokines
CytokinesCytokines
Cytokines
 
Cells of the immune system ppt
Cells of the immune system pptCells of the immune system ppt
Cells of the immune system ppt
 
Haptens
HaptensHaptens
Haptens
 
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANS
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANSORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANS
ORGANS OF IMMUNE SYSTEM PRIMARY AND SECONDARY LYMPHOID ORGANS
 
Cells of the immune system
Cells of the immune systemCells of the immune system
Cells of the immune system
 
The complement system
The complement systemThe complement system
The complement system
 
T and B cell activation
T  and B cell activationT  and B cell activation
T and B cell activation
 
Major Histocompatibility complex
Major Histocompatibility complexMajor Histocompatibility complex
Major Histocompatibility complex
 
Immunological tolerance
Immunological toleranceImmunological tolerance
Immunological tolerance
 

Destaque (20)

Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Cancer and immune system
Cancer and immune systemCancer and immune system
Cancer and immune system
 
Immunology and cancer
Immunology and cancerImmunology and cancer
Immunology and cancer
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
Characteristics of Genetic Code
Characteristics of Genetic CodeCharacteristics of Genetic Code
Characteristics of Genetic Code
 
Cancer immunology
Cancer immunologyCancer immunology
Cancer immunology
 
Cancer immunology
Cancer immunologyCancer immunology
Cancer immunology
 
Genetic code
Genetic codeGenetic code
Genetic code
 
Gene (DNA) Vaccines (Tommy Sato)
Gene (DNA) Vaccines (Tommy Sato)Gene (DNA) Vaccines (Tommy Sato)
Gene (DNA) Vaccines (Tommy Sato)
 
Tumour marker
Tumour markerTumour marker
Tumour marker
 
genetic code
genetic codegenetic code
genetic code
 
cancer immunotherapy
cancer immunotherapycancer immunotherapy
cancer immunotherapy
 
Gentic code
Gentic codeGentic code
Gentic code
 
CANCER
CANCERCANCER
CANCER
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
 
The immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontierThe immunotherapy of cancer: past, present & the next frontier
The immunotherapy of cancer: past, present & the next frontier
 
Nanomedicine
NanomedicineNanomedicine
Nanomedicine
 
Genetic code
Genetic codeGenetic code
Genetic code
 

Semelhante a Tumor antigen

Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptxAnnie Annie
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptxAnnie Annie
 
11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptxnedalalazzwy
 
Tumor Immunology presentation by Sharmista
Tumor Immunology presentation by SharmistaTumor Immunology presentation by Sharmista
Tumor Immunology presentation by SharmistaSharmistaChaitali
 
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of TumorsTUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of TumorsDr. Roopam Jain
 
Immunological aspects of cancer
Immunological aspects of cancerImmunological aspects of cancer
Immunological aspects of cancerPuppala Santosh
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapySweta Shrestha
 
Tumor immunology by nidhi
Tumor immunology by nidhiTumor immunology by nidhi
Tumor immunology by nidhiNidhiLilhare
 
Pharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantporPharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantpormmoney1
 
Tumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxTumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxRagavi32
 
MSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxMSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxLilianNkinda
 
TUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptTUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptUmaShanksr
 
Immunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancyImmunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancyraghunathp
 
tumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptxtumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptxDr Palak borade
 
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...dr.Ihsan alsaimary
 
1. introduction of chemotherapy of cancer
1. introduction of chemotherapy of cancer1. introduction of chemotherapy of cancer
1. introduction of chemotherapy of cancerHarshikaPatel6
 
Immunotherapeutics.pptx
Immunotherapeutics.pptxImmunotherapeutics.pptx
Immunotherapeutics.pptxPronay Mandal
 

Semelhante a Tumor antigen (20)

Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
11. tumour immunology.pptx
11. tumour immunology.pptx11. tumour immunology.pptx
11. tumour immunology.pptx
 
Cancer immunology
Cancer immunologyCancer immunology
Cancer immunology
 
Tumor Immunology presentation by Sharmista
Tumor Immunology presentation by SharmistaTumor Immunology presentation by Sharmista
Tumor Immunology presentation by Sharmista
 
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of TumorsTUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
TUMOUR IMMUNOLOGY, CLINICAL ASPECTS OF NEOPLASIA & Clinical Features of Tumors
 
Tumourclasss
TumourclasssTumourclasss
Tumourclasss
 
Immunological aspects of cancer
Immunological aspects of cancerImmunological aspects of cancer
Immunological aspects of cancer
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapy
 
Tumor immunology by nidhi
Tumor immunology by nidhiTumor immunology by nidhi
Tumor immunology by nidhi
 
Pharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantporPharm immuno14&15 cancer & transplantpor
Pharm immuno14&15 cancer & transplantpor
 
Tumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptxTumor antigens & cancer immunotherapy.pptx
Tumor antigens & cancer immunotherapy.pptx
 
MSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxMSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptx
 
TUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.pptTUMOR IMMUNOLOGY.ppt
TUMOR IMMUNOLOGY.ppt
 
Immunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancyImmunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancy
 
tumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptxtumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptx
 
Tumor Immunology
Tumor ImmunologyTumor Immunology
Tumor Immunology
 
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
 
1. introduction of chemotherapy of cancer
1. introduction of chemotherapy of cancer1. introduction of chemotherapy of cancer
1. introduction of chemotherapy of cancer
 
Immunotherapeutics.pptx
Immunotherapeutics.pptxImmunotherapeutics.pptx
Immunotherapeutics.pptx
 

Último

This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfNirmal Dwivedi
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...Amil baba
 
Tatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf artsTatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf artsNbelano25
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17Celine George
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxPooja Bhuva
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
OSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & SystemsOSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & SystemsSandeep D Chaudhary
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024Elizabeth Walsh
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxJisc
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.MaryamAhmad92
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfSherif Taha
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the ClassroomPooky Knightsmith
 

Último (20)

This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 
Tatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf artsTatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf arts
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
OSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & SystemsOSCM Unit 2_Operations Processes & Systems
OSCM Unit 2_Operations Processes & Systems
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 

Tumor antigen

  • 1. TUMOR CELL TUMOR ANTIGENS SWATHI PRABHAKAR [810014214042] III Year, B.Tech Biotech Anna university [BIT Campus] Trichy 620 024 swathipriyabiotechautbit@gmail.com
  • 2.
  • 3.  Tumor antigen is an antigenic substance produced in tumor cells. i.e., it triggers an immune response in the host.  These antigens are not membrane proteins but are derivatives of cytosolic proteins. i.e.,peptides of cytosolic proteins
  • 4. Two types of tumor antigens have been identified on tumor cells: 1. Tumor-Specific Transplantation Antigens (TSTAs) E.g. : Abnormal products of ras and p53 genes 2. Tumor-Associated Transplantation Antigens (TATAs) E.g. : Epidermal growth factor (EGF) like p97
  • 5. Two genes- red and blueTwo proteins- red and blue
  • 7. Irregular gene expression - Black colour Unwanted protein production
  • 8. Over expressed Normal gene Abnormal protein concentration
  • 9. 1. Unique to tumor cells 2. Do not occur on normal cells in the body. 3. TSTA produced due to physical, chemical or viral mutagens 4. Mutation results in altered cellular proteins. This cellular proteins on cytosolic processing results in novel peptides i.e. tumor antigen
  • 10. 4. This tumor antigen induces cell-mediated immune response by tumor-specific cytosolic T-cell (CTLs) 5. The immune system detects and eliminates these tumor cells by the antigens on the cell surface.
  • 11. • Tumor-associated antigens are not unique to tumor cells. • These are proteins that are expressed on normal cells during fetal development when the immune system is immature and unable to respond but that normally are not expressed in the adult.
  • 12. • Reactivation of the embryonic genes that encode oncofetal proteins in tumor cells results in their expression on the fully differentiated tumor cells. • Tumor-associated antigens may also be proteins that are normally expressed at extremely low levels on normal cells but are expressed at much higher levels on tumor cells.
  • 13. • For example, Transferrin growth factor, designated p97, which aids in the transport of iron into cells. Whereas normal cells express less than 8,000 molecules of p97 per cell, melanoma cells express 50,000–500,000 molecules of p97 per cell
  • 14.
  • 15. 1. Antigens encoded by genes exclusively expressed by tumors. 2. Antigens encoded by variant forms of normal genes that have been altered by mutation. 3. Antigens normally expressed only at certain stages of differentiation or only by certain differentiation lineages. 4. Antigens that are over expressed in particular tumors
  • 16.
  • 17. Following are causes of TSTA Production: 1. Chemical agents E.g. : Methylcholanthrene 2. Physical agents E.g. : Ultraviolet light 3. VIRUS E.g. : Polyoma virus (PV)
  • 18. 1. Chemical agents/ Physical agents -Antigens’ nature varies with respect to 1.1. The type of tissue administered 1.2. The dosage 2. VIRUS - Antigens are specific only to strain irrespective of tissue and concentration.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25. 1 2
  • 26. 1 2
  • 27. • In one method, peptides bound to class I MHC molecules on the membranes of the tumor cells are eluted with acid and purified by high-pressure liquid chromatography (HPLC). In some cases, sufficient peptide is eluted to allow its sequence to be deduced by Edman degradation.
  • 28. In a second approach, cDNA libraries are prepared from tumor cells. These cDNA libraries are transfected transiently into COS cells, which are monkey kidney cells transfected with the gene that codes for the SV40 large-T antigen. When these cells are later transfected with plasmids containing both the tumor-cell cDNA and an SV40 origin of replication, the large-T antigen stimulates plasmid replication, so that up to 104–105 plasmid copies are produced per cell. This results in high-level expression of the tumor-cell DNA.
  • 29. 1. ONCOFETAL TUMOR ANTIGENS E.g. :1. Alpha-fetoprotein (AFP) -Liver cancer 2.Carcinoembryonic antigen (CEA)- advanced Colorectal cancer 2. ONCOGENE PROTEINS AS TUMOR ANTIGENS E.g. : Human breast-cancer cells -Neu protein
  • 30. Tumor antigens Cell-mediated immune responses Humoral immune responses IMMUNE SYSTEM IMMUNE SYSTEM (Major) (Minor) TSTAs CTLs produced against tumor antigens But MHC count on tumor cells reduces thus limiting CTLs Tumor antigens are displayed by class I MHC
  • 31.
  • 32. The recognition of tumor cells by NK cells is MHC restricted Fc receptors on NK cells can bind to antibody-coated tumor cells, leading to ADCC.
  • 33.
  • 34. The recognition of tumor cells by macrophages are not MHC restricted Macrophages cluster around Tumor cells Mediates ADCC utilising lytic enzymes, ROS,RNS. Macrophages produces cytokine – “TNF alpha” induceing hemorrhage and necrosis of the tumor.
  • 35. Immune surveillance theory conceptualized by Paul Ehrlich-states “cancer cells frequently arise in the body but are recognized as foreign and eliminated by the immune system” Later Lewis Thomas suggested that the cell-mediated branch of the immune system had evolved to patrol the body and eliminate cancer cells. Impairment in the immune response results in cancer.
  • 36. 1.Nude mice (Lacking thymus and functional T cells) shows no susceptible to cancer. 2. Individuals on immunosuppressive drugs do show an increased incidence of cancers of the immune system, other common cancers (e.g., lung, breast, and colon cancer) are not increased in these individuals, contrary to what the theory predicts
  • 37. 3. Effect of tumor-cell dosage on the ability of the immune system to respond also are incompatible with the immune surveillance theory. For example, animals injected with very low or very high doses of tumor cells develop tumors, whereas those injected with intermediate doses do not. The mechanism by which a low dose of tumor cells “sneaks through” is difficult to reconcile with the immune surveillance theory
  • 38. 1.Finally, this theory assumes malignant tumors arise only if the immune system is somehow impaired or if the tumor cells lose their immunogenicity, enabling them to escape immune surveillance 2. Cancer cells and normal cells exhibit qualitative antigen differences 3. An immune response can be generated to tumor cells, and therapeutic approaches aimed at increasing that response may serve as a defense against malignant cells tumor evasion of the Immune